局部晚期直肠癌术前新辅助治疗的研究进展  

The progress of preoperative neoadjuvant treatment of locally advanced rectal cancer

作　　者：谭兴颖 唐翠萍[1] 陈杜可 张涛[1] Tan Xingying;Tang Cuiping;Chen Duke;Zhang Tao(Department of Oncology,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)

机构地区：[1]重庆医科大学附属第一医院肿瘤科,重庆400016

出　　处：《现代肿瘤医学》2019年第5期892-895,共4页Journal of Modern Oncology

基　　金：重庆市卫生和计划生育委员会医学科研计划项目(编号:2017MSXM005)

摘　　要：局部晚期直肠癌的主要治疗模式为新辅助放化疗联合全直肠系膜切除术(TME),其主要存在两种模式:长程同步放化疗+TME;短程放疗+TME。随着新辅助治疗的不断发展,有效地提高了局部控制率(4%～6%),但远处转移率仍有待改善(20%～25%)。因局部晚期直肠癌是一组异质性明显的疾病,且目前关于新辅助治疗的具体实施方案争议较大,如何优化治疗模式是进一步研究的热点。The main treatment mode for locally advanced rectal cancer is neoadjuvant chemoradiotherapy combined with total mesorectal excision(TME).There are two main modes:Long-term concurrent chemoradiation+TME,and short-range radiotherapy+TME.With the development of neoadjuvant therapy,the local control rate is effectively increased(4%to 6%),but the distant metastasis rate still needs to be improved(20%to 25%).Because locally advanced rectal cancer is a group of diseases with obvious heterogeneity,and the current regimen of neoadjuvant treatment is controversial,how to optimize treatment mode is a hotspot for further study.

关 键 词：直肠癌 放化疗 治疗 预后 

分 类 号：R735.37[医药卫生—肿瘤]